Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2025.127688 | DOI Listing |
Publication Analysis
Top Keywords
corrigendum phase
4
phase randomized
4
randomized trial
4
trial stride-9
4
stride-9 evaluate
4
evaluate safety
4
safety tolerability
4
tolerability immunogenicity
4
immunogenicity v116
4
v116 population-specific
4
Similar Publications
Corrigendum to "A phase 3 randomized trial (STRIDE-9) to evaluate the safety, tolerability, and immunogenicity of V116, a population-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve Japanese adults ≥65 years of age" [Vaccine 62 (2025) 127456].
Vaccine
September 2025
Merck & Co., Inc., Rahway, NJ, USA. Electronic address:
Corrigendum to "Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial" [Eur J Cancer. 227 (2025) 115674].
Eur J Cancer
August 2025
JSC Biocad, Russian Federation.
Corrigendum to 'Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study'. EBioMedicine 2024;108: 105320.
EBioMedicine
August 2025
Department of Biostatistics, University of Washington, Seattle, WA, USA; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. Electronic address:
Corrigendum to "Development of measurement method for estimating gas-phase concentration of SVOCs in equilibrium with the source material surface at any temperature" [Chemosphere 385 (2025) 144564].
Chemosphere
September 2025
IPREM, IMT Mines Alès, Universite de Pau et des Pays de l'Adour, CNRS, 64000, Pau, France. Electronic address: